Thomas C Hanff
Overview
Explore the profile of Thomas C Hanff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
824
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kyriakopoulos C, Taleb I, Sideris K, Maneta E, Hamouche R, Tseliou E, et al.
J Am Heart Assoc
. 2025 Feb;
14(4):e035464.
PMID: 39950322
Background: Multidisciplinary teams and regionalized care systems have been suggested to improve cardiogenic shock (CS) outcomes. We sought to identify clinical factors associated with successful outcomes for patients developing CS...
2.
Dunlay S, Pinney S, Lala A, Stewart G, McIlvennan C, Wong R, et al.
JAMA Cardiol
. 2025 Feb;
PMID: 39908057
Importance: The advanced ambulatory heart failure (HF) population comprises patients who have progressed beyond the pillars of recommended stage C HF therapies but can still find meaningful life-years ahead. Although...
3.
Goodwin M, Nickel I, Li H, Kagawa H, Kyriakopoulos C, Hanff T, et al.
J Thorac Cardiovasc Surg
. 2024 Nov;
PMID: 39490962
Background: Donation after circulatory death (DCD) heart transplants have increased in the United States with direct procurement with machine perfusion (DPP) and thoracoabdominal normothermic regional perfusion (TA-NRP) techniques. There remains...
4.
Taleb I, Giannouchos T, Kyriakopoulos C, Clawson A, Davis E, Sideris K, et al.
Circ Heart Fail
. 2024 Oct;
17(11):e011709.
PMID: 39421961
Background: Multidisciplinary Shock Teams have improved clinical outcomes for cardiogenic shock, but their implementation costs have not been studied. This study's objective was to compare costs between patients treated with...
5.
Kyriakopoulos C, Sideris K, Taleb I, Maneta E, Hamouche R, Tseliou E, et al.
Circ Heart Fail
. 2024 Aug;
17(9):e011358.
PMID: 39206544
Background: Cardiogenic shock (CS) can stem from multiple causes and portends poor prognosis. Prior studies have focused on acute myocardial infarction-CS; however, acute decompensated heart failure (ADHF)-CS accounts for most...
6.
Chavez M, Anderson M, Kyriakopoulos C, Scott M, Dranow E, Maneta E, et al.
Circ Heart Fail
. 2024 Jul;
17(9):e011827.
PMID: 39051115
Background: Cardiogenic shock (CS) mortality remains near 40%. In addition to inadequate cardiac output, patients with severe CS may exhibit vasodilation. We aimed to examine the prevalence and consequences of...
7.
Kyriakopoulos C, Taleb I, Tseliou E, Sideris K, Hamouche R, Maneta E, et al.
J Am Heart Assoc
. 2024 Jul;
13(14):e032936.
PMID: 38989825
Background: Type 2 diabetes is prevalent in cardiovascular disease and contributes to excess morbidity and mortality. We sought to investigate the effect of glycemia on functional cardiac improvement, morbidity, and...
8.
Dunlay S, Hanff T, Drakos S
JACC Heart Fail
. 2024 Jul;
12(10):1747-1749.
PMID: 38970590
No abstract available.
9.
Yin M, Maneta E, Kyriakopoulos C, Michaels A, Genovese L, Indaram M, et al.
ASAIO J
. 2024 May;
70(12):1060-1066.
PMID: 38810218
Currently, the fully magnetically levitated left ventricular assist device (LVAD) HeartMate 3 (HM3) is the only commercially available device for advanced heart failure (HF) patients. However, the left ventricular (LV)...
10.
Kyriakopoulos C, Selzman C, Giannouchos T, Mylavarapu R, Sideris K, Elmer A, et al.
J Clin Med
. 2024 May;
13(10).
PMID: 38792411
Centrifugal-flow left ventricular assist devices (CF-LVADs) have improved morbidity and mortality for their recipients. Hospital readmissions remain common, negatively impacting quality of life and survival. We sought to identify risk...